Both in Biotechnology
Palisade Bio vs Lineage Cell Therapeutics
Over the past year PALI returned +57.0% and LCTX returned −43.4%; their daily moves had a correlation of 0.14.
PALI +57.0% LCTX −43.4%Growth of $1, one year, split-adjusted
| Metric | PALI | LCTX |
|---|---|---|
| Price | $1.35 | $0.9557 |
| Market cap | $235.3M | $241.7M |
| Today | −6.90% | +0.87% |
| 1 month | −30.8% | −13.1% |
| 6 months | −22.9% | −39.5% |
| Year to date | −42.6% | −42.8% |
| 1 year | +46.5% | −46.6% |
| Revenue growth (YoY) | — | −61.3% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −2114.8% | 138.6% |
| P/E (TTM) | — | — |
| Price / sales | 470.5× | 18.5× |
| Net cash | $125.2M | $50.8M |
| Dividend yield | — | — |
| Volatility (60d) | 72.3% | 49.1% |
| Short % of float | 17.5% | 14.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).